<DOC>
	<DOCNO>NCT01955616</DOCNO>
	<brief_summary>The purpose study , call MOVE-PD , investigate individual Parkinson 's disease ( PD ) chronic constipation ( CC ) respond RM-131 compare placebo . The study look well RM-131 affect frequency spontaneous bowel movement 14-day period . The study also evaluate safety tolerability study drug evaluate whether study drug relief uncomfortable GI symptom related chronic constipation patient unsatisfied therapy try constipation .</brief_summary>
	<brief_title>A Phase 2 Study Evaluate Safety Efficacy RM-131 Patients With Parkinson 's Disease &amp; Chronic Constipation</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Constipation</mesh_term>
	<criteria>Able provide write informed consent willing able comply study procedure . Diagnosis Parkinson 's disease Diagnosis chronic constipation ( CC ) , include experience constipation ~12 week precede 12 month . Regular treatment chronic constipation last 6 month , dissatisfaction current treatment CC , treatment least 2 regimen constipation ( see note end section ) . Stable medication history define change regimen least 2 week prior baseline period Body mass index 1840 kg/m2 Minimental status exam ( screen ) â‰¥26 Female patient must negative serum urine pregnancy test must lactate . For female able bear child , hormonal ( i.e. , oral , implantable , injectable ) singlebarrier method , doublebarrier method birth control must use throughout study . A vasectomized partner allow one conjunction another singlebarrier method . Female patient unable bear child must document case report form ( i.e. , tubal ligation , hysterectomy , postmenopausal [ define minimum one year since last menstrual period ] ) . Postmenopausal status confirm follicle stimulate hormone ( FSH ) woman le 60 year age Note follow medication allow : Selective serotonin reuptake inhibitor ( SSRI ) , SNRI , tricyclic antidepressant permissible stable dos . All medication shall review dis/approved investigator casebycase basis . Benzodiazepines permissible stable dos Stable dos antacid , NSAIDS , Cox2 inhibitor , calcium supplement , thyroid replacement , estrogen replacement , lowdose aspirin cardioprotection , birth control ( adequate back contraception drug interaction birth control conduct ) permissible Dopamine agonist amantadine allow stable dose Deep brain stimulation allow . Unable unwilling provide inform consent comply study procedure Diagnosis secondary constipation beyond Parkinson 's disease Structural metabolic disease affect GI system Unable withdraw follow medication 48 hour prior baseline period throughout study ( except protocol define rescue medication ; see ) : Medications alter GI transit include laxative , prokinetics , erythromycin , narcotic , anticholinergic ( except protocol define rescue medication ) . GABAergic agent Drugs low therapeutic index , warfarin , digoxin , antiseizure medication NOTE : Parkinson 's disease therapy allow . Exceptions Parkinson 's disease medication include : Cogentin ( benztopine ) , Artane ( trihexyphenidyl ) , apomorphone exclude History recent major surgery ( within 60 day screen ) Acute chronic illness history illness , opinion Investigator , could pose threat harm patient obscure interpretation laboratory test result interpretation study data frequent angina , Class III IV congestive heart failure , moderate impairment renal hepatic function , poorly control diabetes , etc . History symptomatic orthostatic hypotension significant history dizziness History hypersensitivity mannitol ingredient active placebo study medication Any clinically significant abnormality screen laboratory physical examination determine Investigator Abnormal 12lead electrocardiogram ( ECG ) , include evidence acute myocardial subendocardial ischemia clinically significant arrhythmias conduction abnormality ( include prolong QTc &gt; 500 msec ) abnormal blood pressure screen except minor deviation deem clinical significance Investigator Acute GI illness within 48 hour baseline period History major GI surgery , except patient uncomplicated appendectomy cholecystectomy allow . ALT AST &gt; 1.5 X upper limit normal ( ULN ) screen Females pregnant breastfeed History excessive alcohol use substance abuse Patient caregiver unable administer daily SC injection Participation investigational clinical study within 30 day prior dose present study Any reason , opinion Investigator , would confound proper interpretation study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Parkinson 's disease , chronic constipation</keyword>
</DOC>